Skip to main content

Donna M. Cochener

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Donna M. Cochener

Donna M. Cochener is recorded as CEO at Neurogene Inc. (NGNE). Neurogene Inc. reported in an 8-K filed December 19, 2023 that Donna M. Cochener was terminated as General Counsel, effective December 18, 2023. Neurogene Inc. reported in an 8-K filed December 19, 2023 that Donna M. Cochener was terminated as Interim Chief Executive Officer, effective December 18, 2023. Neurogene Inc. reported in an 8-K filed April 3, 2023 that Donna M. Cochener was appointed Interim Chief Executive Officer, effective March 31, 2023.

“Each of Donna M. Cochener, Neoleukin's Interim Chief Executive Officer and General Counsel, and Sean Smith, Neoleukin's Interim Chief Financial Officer, had their employment terminated at the Closing of the Merger, which terminations are considered to be without "cause" related to a change in control for purposes of their employment agreements with Neoleukin.”
Neurogene Inc. Form 8-K, filed December 19, 2023 · Read the filing
“Each of Donna M. Cochener, Neoleukin's Interim Chief Executive Officer and General Counsel, and Sean Smith, Neoleukin's Interim Chief Financial Officer, had their employment terminated at the Closing of the Merger, which terminations are considered to be without "cause" related to a change in control for purposes of their employment agreements with Neoleukin.”
Neurogene Inc. Form 8-K, filed December 19, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Neurogene Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.